Westley Nolin

Wes Nolin, Ph.D., is a member of the life sciences team at Morningside Venture Investments where he has performed scientific diligence and assessment for venture capital investments for over 10 years. He is currently on the board of directors of several Morningside portfolio companies, including Vigeo Therapeutics. Prior to graduate school, he worked at the Center for Blood Research at Harvard Medical School studying the molecular role of surfactants in inflammatory lung disease. Wes received his bachelor’s degree from St. Lawrence University and his doctorate degree from Stony Brook University where he completed his doctoral training in the field of molecular and cellular biology with a specialization in immunology.